Q2 EPS Estimates for Vor Biopharma Lifted by HC Wainwright

Vor Biopharma Inc. (NASDAQ:VOR) – Stock analysts at HC Wainwright upped their Q2 2026 earnings per share estimates for shares of Vor Biopharma in a report issued on Monday, May 18th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.67) per share for the quarter, up from their previous forecast of ($0.94). HC Wainwright currently has a “Buy” rating and a $31.00 price target on the stock. The consensus estimate for Vor Biopharma’s current full-year earnings is ($2.68) per share. HC Wainwright also issued estimates for Vor Biopharma’s Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.72) EPS, FY2026 earnings at ($2.88) EPS, FY2027 earnings at ($2.78) EPS, FY2028 earnings at ($1.67) EPS, FY2029 earnings at $1.86 EPS and FY2030 earnings at $4.27 EPS.

Vor Biopharma (NASDAQ:VOR) last released its earnings results on Monday, March 30th. The company reported $307.61 earnings per share (EPS) for the quarter.

Several other equities analysts also recently issued reports on the company. Wells Fargo & Company began coverage on Vor Biopharma in a research report on Thursday, March 19th. They issued an “overweight” rating and a $30.00 target price on the stock. Jefferies Financial Group raised Vor Biopharma to a “strong-buy” rating in a research report on Thursday, April 30th. Wedbush increased their price target on Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Wall Street Zen downgraded Vor Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $42.25.

Vor Biopharma Price Performance

NASDAQ VOR opened at $14.13 on Wednesday. The stock’s fifty day moving average price is $15.08 and its 200 day moving average price is $13.96. Vor Biopharma has a 1 year low of $3.30 and a 1 year high of $65.80.

Institutional Investors Weigh In On Vor Biopharma

Institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Vor Biopharma during the 4th quarter valued at about $36,000. Goldman Sachs Group Inc. grew its position in shares of Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after acquiring an additional 58,247 shares during the period. XTX Topco Ltd acquired a new stake in shares of Vor Biopharma during the 2nd quarter valued at about $66,000. Chung Wu Investment Group LLC acquired a new stake in shares of Vor Biopharma during the 4th quarter valued at about $109,000. Finally, Susquehanna Portfolio Strategies LLC acquired a new stake in shares of Vor Biopharma during the 4th quarter valued at about $134,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Ra Capital Management, L.P. sold 165,150 shares of the firm’s stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total transaction of $2,604,415.50. Following the sale, the director directly owned 2,402,095 shares in the company, valued at $37,881,038.15. This trade represents a 6.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders sold 3,002,903 shares of company stock worth $49,412,176. 0.45% of the stock is currently owned by company insiders.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).